BioVolt BV is a young start-up company that develops advanced photonic devices for in vitro diagnostics.

One of the techniques BioVolt wants to use for this is the MicroRingResonator (MRR). The first application BioVols wants to commercialize is a quick method by which it is possible to determine from a small blood sample whether a diabetic patient suffers from diabetes type I or type II. We are already aware of the presence of biomarkers in the blood. By these biomarkers it is easy to make this distinction. The aim is to demonstrate the presence of these markers with the MRR.

The aim is to demonstrate the presence of these markers with the MRR.

In the recent years the research group NanoPhysicsInterface gained extensive experience in the field of MRR technology and application of biomedical applications. An example is the recently completed TFF project Optofluidic Sensing, in which a sensor for the measuring of acetone levels on human skin was developed. However, these results do not form a perfect parallel for the intended application.

BioVolt does have expertise in the field of biochemistry, but not in the field of the sensor and associated signal processing. That’s why BioVolt asked the research group NanoPhysicsInterface to execute a research in these two areas in order to develop a demonstrator device.

Project Aim / desired results BioVolt

The project goal of BioVolt is the development of a compact device, with which a quick and easy determination of diabetes type I or type II can be made. This is based on Lab-on-a-Chip technology, in which a single drop of blood is applied to the device and analysed quickly. The desired end result is a demonstrator setup, in which the principle is demonstrated. This means a device in which a single drop of blood is applied with a rapid analysis.

The BioVolt project is a cooperation of the research group NanoPhysicsInterface and BioVolt B.V.


The BioVolt project runs from June 1, 2016 until February 28, 2018.

The BioVolt project is funded by TechForFuture